Credit Suisse Group Reiterates “€77.00” Price Target for Bayer (BAYN)

Credit Suisse Group set a €77.00 ($89.53) price objective on Bayer (FRA:BAYN) in a research report report published on Monday morning. The brokerage currently has a buy rating on the healthcare company’s stock.

BAYN has been the subject of several other reports. Goldman Sachs Group set a €116.00 ($134.88) price objective on Bayer and gave the company a buy rating in a research note on Wednesday, September 5th. Barclays set a €105.00 ($122.09) price objective on Bayer and gave the company a buy rating in a research note on Thursday, September 6th. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Bayer in a research note on Monday, October 22nd. Independent Research set a €69.00 ($80.23) price objective on Bayer and gave the company a neutral rating in a research note on Friday. Finally, Deutsche Bank set a €127.00 ($147.67) price objective on Bayer and gave the company a buy rating in a research note on Thursday, October 25th. Seven research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Bayer currently has a consensus rating of Buy and a consensus price target of €92.48 ($107.53).

FRA BAYN opened at €66.85 ($77.73) on Monday. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: Systematic Risk

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit